stockrow
Friday 6 November 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.45
0.07
+5.07%
Follow ZYBT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 29 | 26 | 17 | (24.4%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 61.35 | 48.99 | 20.51 | (40.8) pt | ||||||
| EBT | — | — | — | — | — | — | — | 6 | 2 | (10) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | — | 20.67 | 7.73 | (61.78) | (82.4) pt | ||||||
| Net income | — | — | — | — | — | — | — | 5 | 2 | (12) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.64 | 0.56 | 0.35 | (25.8%) | |||||
| Earnings | — | — | — | — | — | — | — | 0.11 | 0.03 | (0.21) | n/m | ||||||
| Cash flow | — | — | — | — | — | — | — | 0.15 | 0.12 | 0.04 | (47.3%) | ||||||
| Capex | — | — | — | — | — | — | — | (0.03) | (0.08) | (0.04) | +9.5% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 0.11 | 0.04 | 0.00 | (86.1%) | ||||||
| Book value | — | — | — | — | — | — | — | 1.02 | 1.06 | 0.93 | (4.8%) | ||||||
| Shares, m | — | — | — | — | — | — | — | 46 | 46 | 47 | +1.8% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.61 | 0.2 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | 7 | 6 | 2 | (46.3%) | |||||
| Capex | — | — | — | — | — | — | — | (1) | (4) | (2) | +11.6% | ||||||
| Free cash flow | — | — | — | — | — | — | — | 5 | 2 | 0 | (85.8%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 8 | 6 | 2 | (43.6%) | |||||
| Net debt | — | — | — | — | — | — | — | 8 | 9 | 3 | (38.0%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 47 | 48 | 44 | (3.1%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | 2.27 | (15.36) | (15.4) pt | |||||
| ROIC | — | — | — | — | — | — | — | 7.02 | 2.45 | (13.38) | (20.4) pt | ||||||
| ROE | — | — | — | — | — | — | — | 0.00 | 3.26 | (21.66) | (21.7) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 278 | 277 | 269 | (1.6%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.10 | 0.09 | 0.06 | (23.2%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025
Zhengye Biotechnology Holding Limited vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CPIX Cumberland Pharmaceuticals Inc. | $75.1M | — (loss-making) | — (loss-making) | −98.46% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| TLPH Talphera, Inc. | $52.4M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −33.11% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CTOR Citius Oncology, Inc. | $46.5M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | Compare |
| ZYBT Zhengye Biotechnology Holding Limited | $41.0M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | |
| INCR InterCure Ltd. | $39.1M | 6.2× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | Compare |
| SCYX SCYNEXIS, Inc. | $32.8M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| RMTI Rockwell Medical, Inc. | $30.6M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| IXHL Incannex Healthcare Inc. | $28.5M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CPHI China Pharma Holdings, Inc. | $22.8M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| Median of peers | $35.9M | — | — | −8.56% | — | −23.02% | 83.54% | (78.48%) |